- Written communication relating to an issuer or third party (SC TO-C)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

PHARMANET DEVELOPMENT GROUP, INC.

(Name of Subject Company (Issuer))

PDGI ACQUISITION CORP. (Offeror)

JLL PHARMANET HOLDINGS, LLC (Parent of Offeror)

JLL PARTNERS FUND V, L.P.

JLL PARTNERS FUND VI, L.P.

(Name of Filing Persons)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

717148100

(CUSIP Number of Class of Securities)

PDGI Acquisition Corp.

c/o JLL Partners, Inc.

450 Lexington Avenue, 31st Floor

New York, NY 10017

Attention: Peter M. Strothman

Tel: 212-286-8600

(Name, Address and Telephone Number of Person Authorized

to Receive Notices and Communications on Behalf of the filing person)

Copy to:

Steven J. Daniels, Esq.

One Rodney Square

P.O. Box 636

Wilmington, Delaware 19899

Tel: 302-651-3000

CALCULATION OF FILING FEE


Transaction Valuation		Amount of Filing Fee

$N/A		$N/A

o Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


Amount Previously Paid:	N/A	Filing Party:	N/A
Form or Registration No.	N/A	Date Filed:	N/A

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

third-party tender offer subject to Rule 14d-1.

issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: o

This filing relates solely to preliminary communications made before the commencement of a planned tender offer by PDGI Acquisition Corp. (the "Purchaser"), a wholly-owned subsidiary of JLL PharmaNet Holdings, LLC (the "Parent"), for all of the outstanding common stock, including the associated preferred share purchase rights, of PharmaNet Development Group, Inc. (the "Company"), to be commenced pursuant to the Agreement and Plan of Merger, dated February 3, 2009, among the Parent, the Purchaser and the Company. All of the membership interests of the Parent are owned by JLL Partners Fund V, L.P. and JLL Partners Fund VI, L.P.

The exhibit is neither an offer to purchase nor solicitation of an offer to sell securities. The tender offer for the outstanding shares of the Company's common stock described in this filing has not commenced. At the time the offer is commenced, the Purchaser will file a tender offer statement on Schedule TO with the Securities and Exchange Commission, and the Company will file a solicitation/recommendation statement on Schedule 14D-9, with respect to the offer. The tender offer statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the solicitation/recommendation statement will contain important information that should be read carefully before any decision is made with respect to the tender offer. Those materials will be made available to the Company's stockholders at no expense to them. In addition, all of those materials (and all other offer documents filed with the SEC) will be available at no charge on the SEC's website: www.sec.gov .

Exhibit Index